SGLT2 inhibitor outcome trials: Future opportunities - PACE-CME

SGLT inhibitor outcome trials Future opportunities

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Finerenone does not alter vascular stiffness in patients with T2D and CKD
Finerenone does not alter vascular stiffness in patients with T2D and CKD
ESC Heart Failure 2025
Finerenone does not alter vascular stiffness in patients with T2D and CKD
- Atsushi Tanaka, MD, PhD
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
ESC Heart Failure 2025
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
- Varun Sundaram, MD, PhD
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
ACC.25
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
- Darren K. McGuire, MD
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
ACC.25
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
- Marc Bonaca, MD